Merrill Lynch analyst Hitoshi Kuriyama says there is also a greater-than-expected deterioration in Sony's other business lines.

FORBES: Magazine Article

Monma Y, Niu K, Iwasaki K, Tomita N, Nakaya N, Hozawa A, Kuriyama S, Takayama S, Seki T, Takeda T, Yaegashi N, Ebihara S, Arai H, Nagatomi R, Tsuji I.

FORBES: Chinese Medicine Infiltrates Scientific Publishing

Merrill's Kuriyama maintains a sell recommendation.

FORBES: Magazine Article